Bharat Biotech rolls out nextgen oral Cholera vax HILLCHOL, ramps up manufacturing

Bharat Biotech International Limited announced the release of HILLCHOL, an innovative single-strain oral cholera vaccine. Developed under license from Hilleman Laboratories, HILLCHOL aims to mitigate the global cholera vaccine shortage. The new facilities in Hyderabad and Bhubaneswar can produce up to 200 million doses annually, with the vaccine demonstrating proven safety and efficacy through extensive clinical trials.